Skip to main content
Diabetes, CVD patients may improve life expectancy with empagliflozin

Researchers analyzed data on 7,020 type 2 diabetes patients with cardiovascular disease from the EMPA-REG OUTCOME trial and found that the expected residual years of survival among those who received empagliflozin was 32.1 years at age 45 and 7.7 years at age 80, compared with 27.6 years and 6.7 years among those on placebo, respectively. The findings in the journal Circulation showed that empagliflozin could prolong a patient's life span by an average of 2.5 years, said study lead author Brian Claggett.

Full Story: